Drugs / EYU688
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06006559 | Feb 2024 → Jul 2027 expected | dengue disease | Novartis Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | EYU688 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06006559 ↗ |
| Route | Oral | “EYU688 administered by oral route” NCT06006559 ↗ |